findphrase.net
 

Phrases contain exact "meningococcal polysaccharide" from credible sources

EXACT :

Molecular size distribution of meningococcal polysaccharide vaccine is a readily identifiable parameter that directly correlates with the immunogenicity. In this paper, we report a size exclusion chromatography method to determine the molecular size distribution and distribution coefficient value of meningococcal polysaccharide serogroups A, C ... <br><strong>Author:</strong> Imran Khan, K. M. Taufiqur Rahman, S. M. Saad Us Siraj, Mahbubul Karim, Abdul Muktadir, Arpan Mahesh... <br><strong>Publish Year:</strong> 2016
pubmed.ncbi.nlm.nih.gov


Feb 11, 1998 · The meningococcal polysaccharide vaccine was effective against serogroup C meningococcal disease in this community outbreak. Although specific barriers to vaccination were not identified, older age was a risk factor for nonvaccination in the target population of 2- to 29-year-olds. In future outbrea … <br><strong>Author:</strong> Nancy Rosenstein, Orin Levine, Jeffery P. Taylor, Deborah Evans, Brian D. Plikaytis, Jay D. Wenger, ... <br><strong>Publish Year:</strong> 1998
pubmed.ncbi.nlm.nih.gov


Abstract. It is now 5 years since the UK became the first country to introduce the serogroup C meningococcal polysaccharide-protein conjugate vaccines (MenC) into its routine immunisation schedule. This article reviews the global use of MenC with particular reference to the range of immunisation strategies used internationally. <br><strong>Author:</strong> Matthew D Snape, Andrew J Pollard <br><strong>Publish Year:</strong> 2005
pubmed.ncbi.nlm.nih.gov


Apr 03, 2021 · Background: Although China's Expanded Program on Immunization (EPI) provides two doses of group A meningococcal polysaccharide vaccine (MPV-A) for children younger than 2 y, more self-paying group A and group C meningococcal polysaccharide conjugate vaccine (MCV-AC) has been used as an alternative to MPV-A, to prevent Neisseria meningitidis serogroup C … <br><strong>Author:</strong> Xinren Che, Yan Liu, Jun Wang, Yuyang Xu, Xuechao Zhang, Wenwen Gu, Wei Jiang, Jian Du, Xiaoping Zha... <br><strong>Publish Year:</strong> 2021
pubmed.ncbi.nlm.nih.gov


Jun 03, 2014 · Invasive bacterial meningitis caused by Neisseria meningitidis can be prevented by active immunization with meningococcal polysaccharide or polysaccharide-protein conjugate vaccines. In a tetravalent A/C/Y/W-135-DT meningococcal conjugate vaccine vial, or in a final formulated bulk, accurate identification and quantification of each ...
pubmed.ncbi.nlm.nih.gov


The aim of this work is to present a review of the methods used to obtain a platform of MAbs against Neisseria meningitidis polysaccharide antigens to use as an analytical tool for quality control of anti-meningococcal polysaccharide (Ps) vaccines. The MAbs obtained are used in five sandwich ELISAs developed for Ps quantification.
pubmed.ncbi.nlm.nih.gov


Meningococcal polysaccharide vaccines against serogroup A and C are efficacious and have been widely used, often in combination with serogroup Y and W135 components. Their relative lack of immunogenicity in young children and infants can be overcome by conjugation to a protein carrier. The effectiveness of serogroup C glycoconjugate vaccines in ...
pubmed.ncbi.nlm.nih.gov


Abstract. Previous studies with group C meningococcal polysaccharide-tetanus toxoid (GCMP-TT) conjugates had suggested that the GCMP O-acetyl group masked the protective epitope for group C meningococci through steric hindrance or altered conformations. For this report, we confirmed this phenomenon and performed comparative studies with group Y ...
pubmed.ncbi.nlm.nih.gov


A series of group C meningococcal polysaccharide-tetanus toxoid (GCMP-TT) conjugates were prepared as vaccines with varying percentages of O-acetylation at the C-7 and C-8 positions of sialic acid residues in the polysaccharide (PS). The immune response in mice was highly dependent on the degree of O-acetylation. Less O-acetylation resulted in ...
pubmed.ncbi.nlm.nih.gov


Jul 05, 2018 · Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial
pubmed.ncbi.nlm.nih.gov


A precipitation method using deoxycholate/HCI has been applied successfully to separate unconjugated free polysaccharide from carrier protein-bound material in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines. The method effectively separated free and bound polysaccharide in conjuga …
pubmed.ncbi.nlm.nih.gov


Potency of meningococcal polysaccharide-protein conjugate vaccines relies on the polysaccharide content to prevent meningitis. NIBSC, as the official national control laboratory in UK, analysed ten different mono- and multi-meningococcal conjugate vaccines, using established International Standards for meningococcal serogroups A, C, W, Y and X, by resorcinol or …
pubmed.ncbi.nlm.nih.gov


As for the small amount of LPS present in a meningococcal polysaccharide preparation, similar LPS content was obtained when measured by the three methods suggesting that the LPS is not bound to the polysaccharide in contrast to that in the proteins mentioned above. The purified meningococcal LPS was pyrogenic in rabbits at 1 ng/kg.
pubmed.ncbi.nlm.nih.gov


Combination conjugate vaccines, containing more than one meningococcal polysaccharide, have been developed to broaden protection against the disease. A tetravalent meningococcal A, C, Y and W-135 conjugate vaccine was licensed for use in 11-55 year old adolescents and adults in the US in January 2005, and subsequently also in 2-11 year old ...
pubmed.ncbi.nlm.nih.gov


Jul 15, 2019 · Near-infrared (NIR) spectroscopy is an attractive tool for pharmaceutical analyses. The main purpose of this study was to assess the potential of NIR spectroscopy coupled with different multivariate classification tools for the identification of meningococcal polysaccharide serogroups A and C. Moreo …
pubmed.ncbi.nlm.nih.gov


US Brand Name Menactra Descriptions Meningococcal polysaccharide diphtheria conjugate vaccine is<strong> an active immunizing agent used to prevent infection by certain groups of</strong> …
www.mayoclinic.org


MENINGOCOCCAL POLYSACCHARIDE VACCINE (muh ning goh KOK kal vak SEEN) is<strong> a vaccine to protect from bacterial meningitis.</strong> This vaccine does not contain live bacteria. It …
my.clevelandclinic.org


Dec 15, 2021 · Applies to meningococcal polysaccharide vaccine: parenteral solution for im use. Side effects include: MenACWY-D ( Menactra ® ): Injection site reactions (e.g., pain, …
www.drugs.com


Meningococcal Polysaccharide Vaccine (MPSV4) *HIGH RISK CONDITIONS/GROUPS • College freshmen, living in dormitories • Persons with functional or anatomic asplenia, or persistent …
dph.georgia.gov


Oct 07, 2020 · The first vaccine --<strong> meningococcal polysaccharide</strong> vaccine or MPSV4 -- was approved in 1978. It's made with the antigens contained in the outer polysaccharide or sugar …
www.webmd.com


Meningococcal polysaccharide vaccine<strong> (MPSV-4), Menomune,</strong> has been available since the 1970s. It may be used if MCV-4 is not available, and is the only meningococcal vaccine …
en.wikipedia.org


Feb 24, 2009 · Availability and storage of meningococcal polysaccharide vaccinesA meningococcal polysaccharide vaccine is a freeze-dried preparation of the group-specific …
www.sciencedirect.com


Meningococcal Polysaccharide Vaccine,<strong></strong> Groups A, C, Y and W-135 Combined. Menomune-A/C/Y/W-135.
www.fda.gov


<strong>Meningococcal Polysaccharide</strong> Vaccine, Diphtheria Conjugate (Intramuscular Route) Side Effects Drug information provided by: IBM Micromedex Along with its needed effects, a …
www.mayoclinic.org


It is now 5 years since the<strong> UK became</strong> the<strong> first country to introduce the serogroup C meningococcal polysaccharide-protein conjugate vaccines (MenC) into its routine</strong> …
pubmed.ncbi.nlm.nih.gov


Sep 08, 2017 · Generic Name Meningococcal polysaccharide vaccine group A DrugBank Accession Number DB13889 Background. Meningococcal group A polysaccharide is group …
go.drugbank.com


Aug 15, 2022 · The Meningococcal Polysaccharide Vaccine market report broadly elucidates the regional scope of this industry. It also divides the geographical expanse into United States, …
www.fractovia.org


Sep 08, 2017 · Generic Name Meningococcal polysaccharide vaccine group C DrugBank Accession Number DB13890 Background. Meningococcal group C polysaccharide is group …
go.drugbank.com


Feb 20, 2016 · Physicochemical methods are the primary tests used to ensure that batches of <strong>meningococcal polysaccharide</strong> (PS) antigens are manufactured consistently to those shown to be safe and effective in clinical trials. Although modern physicochemical methods of analysis providing structural information about the antigens have been developed and used ...
pubmed.ncbi.nlm.nih.gov


Feb 23, 2022 · Immunogenicity of <strong>meningococcal polysaccharide</strong> conjugate vaccine as a replacement for <strong>meningococcal polysaccharide</strong> vaccine in children in Guangzhou, China Vaccine . 2022 Feb 23;40(9):1370-1375. doi: 10.1016/j.vaccine.2021.09.021.
pubmed.ncbi.nlm.nih.gov


The Sanofi Pasteur <strong>meningococcal polysaccharide</strong> A + C vaccine (Men-AC) was licensed in China in 1995. Immunogenicity and safety of a single dose of Men-AC against a similar marketed vaccine, the Lanzhou Institute serogroups A and C vaccine (Lanzhou-AC), were evaluated in children 2 to 6 y of age. Antibody titers were determined before and on ...
pubmed.ncbi.nlm.nih.gov


Since 1981, a tetravalent <strong>meningococcal polysaccharide</strong> vaccine has been available in the US but it has been limited to high-risk patients and outbreak settings. In 2005, a tetravalent <strong>polysaccharide meningococcal</strong> conjugate vaccine (MCV4) was licensed for routine use in the US. Objective: To assess the immunogenicity and safety of MCV4, and to ...
pubmed.ncbi.nlm.nih.gov


<strong>Meningococcal</strong> disease is one of the most feared and serious infections in the young and its prevention by vaccination is an important goal. The high degree of antigenic variability of the organism makes the meningococcus a challenging target for vaccine prevention. <strong>Meningococcal polysaccharide</strong> vaccines against serogroup A and C are efficacious ...
pubmed.ncbi.nlm.nih.gov


Abstract. It is now 5 years since the UK became the first country to introduce the serogroup C <strong>meningococcal polysaccharide</strong>-protein conjugate vaccines (MenC) into its routine immunisation schedule. This article reviews the global use of MenC with particular reference to the range of immunisation strategies used internationally.
pubmed.ncbi.nlm.nih.gov


Jul 15, 2019 · Near-infrared (NIR) spectroscopy is an attractive tool for pharmaceutical analyses. The main purpose of this study was to assess the potential of NIR spectroscopy coupled with different multivariate classification tools for the identification of <strong>meningococcal polysaccharide</strong> serogroups A and C. Moreo …
pubmed.ncbi.nlm.nih.gov


Combination conjugate vaccines, containing more than one <strong>meningococcal polysaccharide</strong>, have been developed to broaden protection against the disease. A tetravalent <strong>meningococcal</strong> A, C, Y and W-135 conjugate vaccine was licensed for use in 11-55 year old adolescents and adults in the US in January 2005, and subsequently also in 2-11 year old ...
pubmed.ncbi.nlm.nih.gov


<strong>Meningococcal polysaccharide</strong> (Men-Ps) vaccine immunogenicity following either primary immunization or revaccination in adults was evaluated. The study population consisted of subjects who have received tetravalent Men-Ps vaccine once (group 1) or at least twice, with a 2-6 dose range (group 2). Human leucocyte antigen (HLA)-typing was performed ...
pubmed.ncbi.nlm.nih.gov


Jun 03, 2014 · Invasive bacterial meningitis caused by Neisseria meningitidis can be prevented by active immunization with <strong>meningococcal polysaccharide</strong> or <strong>polysaccharide</strong>-protein conjugate vaccines. In a tetravalent A/C/Y/W-135-DT <strong>meningococcal</strong> conjugate vaccine vial, or in a final formulated bulk, accurate identification and quantification of each ...
pubmed.ncbi.nlm.nih.gov


A precipitation method using deoxycholate/HCI has been applied successfully to separate unconjugated free <strong>polysaccharide</strong> from carrier protein-bound material in <strong>meningococcal polysaccharide</strong>-diphtheria toxoid conjugate vaccines. The method effectively separated free and bound <strong>polysaccharide</strong> in conjuga …
pubmed.ncbi.nlm.nih.gov


A series of group C <strong>meningococcal polysaccharide</strong>-tetanus toxoid (GCMP-TT) conjugates were prepared as vaccines with varying percentages of O-acetylation at the C-7 and C-8 positions of sialic acid residues in the <strong>polysaccharide</strong> (PS). The immune response in mice was highly dependent on the degree of O-acetylation. Less O-acetylation resulted in ...
pubmed.ncbi.nlm.nih.gov


Abstract. Previous studies with group C <strong>meningococcal polysaccharide</strong>-tetanus toxoid (GCMP-TT) conjugates had suggested that the GCMP O-acetyl group masked the protective epitope for group C meningococci through steric hindrance or altered conformations. For this report, we confirmed this phenomenon and performed comparative studies with group Y ...
pubmed.ncbi.nlm.nih.gov


Meningococcal polysaccharide diphtheria conjugate vaccine is<strong> an active immunizing agent used to prevent infection by certain groups of meningococcal bacteria.</strong> The vaccine …
www.mayoclinic.org


MENINGOCOCCAL POLYSACCHARIDE VACCINE (muh ning goh KOK kal vak SEEN) is<strong> a vaccine to protect from bacterial meningitis.</strong> This vaccine does not contain live bacteria. It …
my.clevelandclinic.org


Dec 15, 2021 · Applies to <strong>meningococcal polysaccharide</strong> vaccine: parenteral solution for im use. Side effects include: MenACWY-D ( Menactra ® ): Injection site reactions (e.g., pain, …
www.drugs.com


<strong>Meningococcal polysaccharide vaccine systemic is used in the treatment of: Meningococcal Meningitis Prophylaxis</strong> Further information Always consult your healthcare …
www.drugs.com


<strong>Meningococcal Polysaccharide</strong> Vaccine (MPSV4) *HIGH RISK CONDITIONS/GROUPS • College freshmen, living in dormitories • Persons with functional or anatomic asplenia, or …
dph.georgia.gov


<strong>Meningococcal polysaccharide</strong> vaccine<strong> (MPSV-4), Menomune,</strong> has been available since the 1970s. It may be used if MCV-4 is not available, and is the only meningococcal vaccine …
en.wikipedia.org


Sep 08, 2017 · Generic Name <strong>Meningococcal polysaccharide</strong> vaccine group A DrugBank Accession Number DB13889 Background. <strong>Meningococcal</strong> group A <strong>polysaccharide</strong> is group …
go.drugbank.com


<strong>It is now 5 years since the UK became the first country to introduce the serogroup C meningococcal polysaccharide-protein conjugate vaccines (MenC) into its routine</strong> …
pubmed.ncbi.nlm.nih.gov


Aug 15, 2022 · The<strong> Meningococcal Polysaccharide Vaccine market report specifically evaluates the product expanse of the industry space in question.</strong> With respect to the …
www.fractovia.org


The immunogenicity to several <strong>meningococcal polysaccharide</strong>-protein conjugates was evaluated in mice. The puri- fied <strong>polysaccharide</strong> from N. meningitidis serogroup C (PsC) was …
www.academia.edu


<strong>Meningococcal Polysaccharide</strong> Vaccine, Diphtheria Conjugate (Intramuscular Route) Print. Sections. Description and Brand Names; Before Using; Proper Use; Precautions; Side Effects; …
www.mayoclinic.org


A series of group C meningococcal polysaccharide-tetanus toxoid (GCMP-TT) conjugates were prepared as vaccines with varying percentages of O-acetylation at the C-7 and C-8 positions …
pubmed.ncbi.nlm.nih.gov


Feb 01, 2022 · Appropriate studies have not been performed on the relationship of age to the effects of <strong>meningococcal polysaccharide</strong> diphtheria conjugate vaccine in adults older than …
www.mayoclinic.org


Phrases contain similar "meningococcal polysaccharide" from credible sources

SIMILAR :

<strong>Meningococcal conjugate vaccines</strong> may be used for the same indications than <strong>polysaccharides vaccines,</strong> but also for long term individual protection (both for patient at high risk or without risk factor) and in national immunization programs. They must replace polysaccharide<strong> vaccines</strong> notably because of the risk of immunologic hypo-responsiveness. <br><strong>Author:</strong> R. Cohen, C. Levy <br><strong>Publish Year:</strong> 2012
pubmed.ncbi.nlm.nih.gov


Objective: This article reviews data encompassing the pharmacology, efficacy, and safety of MenACWY-TT (MenQuadfi), a conjugate vaccine to prevent meningococcal disease from serogroups A, C, W, Y. Data sources: A literature review was conducted in PubMed, MEDLINE, and ClinicalTrials.gov from inception up to July 2021, using the search terms MenQuadfi, …
pubmed.ncbi.nlm.nih.gov


Objectives: This phase III study assessed the safety and immunogenicity of MenACWY-CRM, a quadrivalent meningococcal conjugate vaccine, administered with routine vaccines starting at 2 months of age. Methods: Healthy infants received MenACWY-CRM in a two- or three-dose primary infant series plus a single toddler dose. In addition, a two-dose toddler catch-up series …
pubmed.ncbi.nlm.nih.gov


Jun 02, 2022 · Background: The aim of this study was to investigate the immunogenicity and safety of the enterovirus 71 vaccine (EV71 vaccine) administered alone or simultaneously. Methods: A multi-center, open-label, randomized controlled trial was performed involving 1080 healthy infants aged 6 months or 8 months from Shandong, Shanxi, Shaanxi, and Hunan …
pubmed.ncbi.nlm.nih.gov


In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A polysaccharide (PS) O-acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY polysaccharide vaccin …
pubmed.ncbi.nlm.nih.gov


Each dose contains 4 micrograms (µg)<strong> each of meningococcal A, C, W, and Y polysaccharides conjugated</strong> to approximately 48 µg of diphtheria toxoid protein carrier. It …
www.cdc.gov


All 11 to 12 year olds should get a MenACWY vaccine, with a booster dose at 16 years old. Teens and young adults (16 through 23 years old) also may get a MenB vaccine. CDC also …
www.cdc.gov


<strong>Meningococcal</strong> polysaccharide vaccine systemic is used in the treatment of:<strong> Meningococcal Meningitis</strong> Prophylaxis Further information Always consult your healthcare provider to ensure …
www.drugs.com


Aug 06, 2021 · Meningococcal ACWY vaccine can help protect against meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can …
www.cdc.gov


Meningococcal (Groups A, C, Y and W-<strong>135)</strong> Polysaccharide Diphtheria Toxoid Conjugate Vaccine. Menactra.
www.fda.gov


Vaccines against the polysaccharide meningococcal capsule lead to the<strong> prevention of invasive meningococcal diseases</strong> due to serotypes A, C, Y, W135. Polysaccharide vaccines, …
pubmed.ncbi.nlm.nih.gov


Mar 01, 2018 · U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 1-888-INFO-FDA (1-888-463-6332) Contact FDA
www.fda.gov


<strong>Meningococcal</strong> conjugate vaccines may be used for the same indications than polysaccharides vaccines, but also for long term individual protection (both for patient at high risk or without risk factor) and in national immunization programs. They must replace <strong>polysaccharide</strong> vaccines notably because of the risk of immunologic hypo-responsiveness. <br><strong>Author:</strong> R. Cohen, C. Levy <br><strong>Publish Year:</strong> 2012
pubmed.ncbi.nlm.nih.gov


Objective: This article reviews data encompassing the pharmacology, efficacy, and safety of MenACWY-TT (MenQuadfi), a conjugate vaccine to prevent <strong>meningococcal</strong> disease from serogroups A, C, W, Y. Data sources: A literature review was conducted in PubMed, MEDLINE, and ClinicalTrials.gov from inception up to July 2021, using the search terms MenQuadfi, … <br><strong>Author:</strong> Jessica Huston, Kevin Galicia, Eric F Egelund <br><strong>Publish Year:</strong> 2021
pubmed.ncbi.nlm.nih.gov


Background: Controlled trials over two decades ago showed that the <strong>polysaccharide</strong> vaccine prevented serogroup A <strong>meningococcal</strong> meningitis. Subsequent non-experimental studies suggested age-specific variations in the duration of protection among young children. Objectives: To determine the effect of <strong>polysaccharide</strong> serogroup A vaccine for preventing serogroup A … <br><strong>Author:</strong> Mahomed Patel, Chin‐kei Lee <br><strong>Publish Year:</strong> 2005
pubmed.ncbi.nlm.nih.gov


Jun 02, 2022 · Background: The aim of this study was to investigate the immunogenicity and safety of the enterovirus 71 vaccine (EV71 vaccine) administered alone or simultaneously. Methods: A multi-center, open-label, randomized controlled trial was performed involving 1080 healthy infants aged 6 months or 8 months from Shandong, Shanxi, Shaanxi, and Hunan …
pubmed.ncbi.nlm.nih.gov


In this study, we compared the immunogenicities of two lots of <strong>meningococcal</strong> ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A <strong>polysaccharide</strong> (PS) O-acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY <strong>polysaccharide</strong> vaccin …
pubmed.ncbi.nlm.nih.gov


Background/purpose: <strong>Meningococcal</strong> disease, including meningitis and sepsis, usually follows an invasive infection by Neisseria meningitidis, and is a major cause of death and morbidity worldwide. Currently available <strong>meningococcal</strong> vaccines that consist of pure capsular polysaccharides (serogroups A, C, W-135 and Y) are generally safe and efficacious in adults …
pubmed.ncbi.nlm.nih.gov


A protein-<strong>meningococcal</strong> serogroup C capsular <strong>polysaccharide</strong> (CPS-C) conjugate was selected as the model antigen for this study. After subcutaneous immunization of Balb/C mice, the conjugate mixed with CPS-A induced higher anti-CPS-C IgG and IgG(2a) antibody levels and higher anti-<strong>meningococcal</strong> serogroup C bactericidal titers than the conjugate ...
pubmed.ncbi.nlm.nih.gov


<strong>Meningococcal</strong> Disease is a type of illness caused by Neisseria Meningitidis bacteria. There are three types of <strong>meningococcal</strong> vaccines available in the US, and they are: <strong>Meningococcal</strong> …
www.cdc.gov


10 µg of lyophilized meningococcal serogroup<strong> A (MenA) capsular polysaccharide conjugated to CRM197 5 μg each of capsular polysaccharide</strong> of serogroup C, W, and Y (MenCWY) …
www.cdc.gov


Jul 15, 2019 · Near-infrared (NIR) spectroscopy is an attractive tool for pharmaceutical analyses. The main purpose of this study was to assess the potential of NIR spectroscopy coupled with …
pubmed.ncbi.nlm.nih.gov


Oct 07, 2020 · The<strong> meningococcal</strong> conjugate vaccine or MCV4 was approved in 2005. It uses<strong> antigens</strong> taken from the<strong> polysaccharide</strong> capsule and then bound to a separate protein that …
www.webmd.com


The deltoid region is the preferred administration site. Single dose vials should be used immediately after reconstitution. Multidose vials may be used for up to 35 days after …
www.drugs.com


<strong>Meningococcal</strong> (Groups A, C, Y and W-<strong>135) Polysaccharide</strong> Diphtheria Toxoid Conjugate Vaccine. Menactra.
www.fda.gov


<strong>Vaccines against the polysaccharide meningococcal capsule lead to the prevention of invasive meningococcal diseases due to serotypes A, C, Y, W135.</strong> Polysaccharide
pubmed.ncbi.nlm.nih.gov



meningococcal polysaccharide

[meningococcal* ˌpɑˌliˈsækərˌaɪd]